Oral αCT11-loaded mEVs (XOlacta) mitigate lethal radiation injury while preserving tumor radiosensitivity
Background
Ionizing radiation (IR) is a cornerstone of cancer therapy, but its efficacy is often limited by severe normal-tissue toxicity, which restricts dose escalation. Beyond therapeutic contexts, high-dose radiation exposure from accidents or mass casualties poses a significant threat, necessitating urgent development of practical radiomitigators for radiosensitive organs. Current strategies often lack the specificity or ease of administration required for widespread use, creating a critical gap for agents that can protect healthy tissues while maintaining tumor radiosensitivity. This study explores a novel oral approach.
Study Design
Researchers investigated orally delivered milk extracellular vesicles (mEVs) loaded with the connexin43 carboxyl-terminal peptide αCT11 (named XOlacta) in two murine models. A 14 Gy total-body irradiation model was used to assess radiomitigation, with a single oral XOlacta dose given 1 h or 24 h post-irradiation. A syngeneic GL261 glioma radiotherapy model evaluated normal tissue protection alongside tumor radiosensitivity. Biodistribution was tracked using fluorescently labelled mEVs.
Results
A single oral dose of XOlacta given 1 h after 14 Gy total-body irradiation (TBI) conferred 42% 30-day survival, despite an expected 100% lethality from this challenge. This significant protective effect was accompanied by marked preservation of ileal architecture and femoral bone marrow cellularity. Crucially, a significant survival benefit was retained even when XOlacta dosing was delayed to 24 h post-irradiation. Biodistribution studies using fluorescently labelled mEVs demonstrated radiation-enhanced uptake in key radiosensitive tissues, including the brain, gut, and bone marrow, suggesting an injury-licensed targeting mechanism. Furthermore, in a syngeneic
GL261glioma radiotherapy model, XOlacta effectively protected normal tissues from radiation damage without diminishing the tumor's radiosensitivity, indicating a selective protective effect. These findings highlight the potent radiomitigative properties of oralαCT11-loaded mEVs.
Key Findings
- Oral XOlacta conferred 42% 30-day survival against lethal 14 Gy total-body irradiation.
- XOlacta preserved ileal architecture and femoral bone marrow cellularity post-radiation injury.
- Survival benefit was retained even when XOlacta dosing was delayed to 24 h post-irradiation.
- XOlacta protected normal tissues in glioma mice without diminishing tumor radiosensitivity.
- Radiation-enhanced uptake of mEVs in brain, gut, and bone marrow suggests injury-licensed targeting.
Why It Matters
This research introduces a potent, non-parenteral radiomitigator that could revolutionize both cancer radiotherapy and emergency radiation exposure management. For clinicians, XOlacta offers a strategy to potentially escalate radiation doses in cancer therapy by protecting healthy tissues, thereby improving treatment efficacy without increasing side effects. For those concerned with accidental or mass-casualty radiation exposures, an orally administered agent like XOlacta provides a practical and accessible solution for mitigating severe injury to radiosensitive organs like the gut and bone marrow. The ability to delay dosing up to 24 hours post-exposure significantly broadens its applicability in real-world scenarios, moving closer to a usable protocol for broad protection.
act11
xolacta
radiation injury
radiomitigator
cancer therapy
glioma